Document is current
Any future updates will be listed below
-
Authors
Kato, Koji https://orcid.org/0000-0002-5815-4585
Inamoto, Yoshihiro https://orcid.org/0000-0003-4881-0427
Kawakita, Toshiro
Onishi, Yasushi https://orcid.org/0000-0003-0032-6994
Matsuoka, Ken-ichi
Shiratori, Soichi https://orcid.org/0000-0002-5528-7112
Ikegame, Kazuhiro
Hiramoto, Nobuhiro https://orcid.org/0000-0002-0472-6680
Toyosaki, Masako
Katayama, Yuta https://orcid.org/0000-0001-5054-9104
Koga, Yuhki
Murayama, Shun
Sasagawa, Yuji
Shindo, Mami
Teshima, Takanori
Hatake, Kiyohiko
Maeda, Yoshinobu https://orcid.org/0000-0003-1634-5487
- License Information
-
More Information
Article History
Received: 14 August 2025
Revised: 6 November 2025
Accepted: 19 November 2025
First Online: 26 November 2025
Competing interests
: KK reports honoraria from Chugai, Kyowa-Kirin, Novartis Pharma, and Takeda; and research funding from AbbVie, Celgene, Chugai, Daiichi Sankyo, Eisai, Janssen, Kyowa Kirin, Novartis, Ono, and Takeda. YI reports honoraria and research funding from Meiji Seika Pharma. YO reports honoraria from Amgen, Asahi Kasei; and research funding from Incyte, Janssen, Meiji Seika Pharma, Novartis, Pfizer, and Sumitomo Pharma. SS reports research funding from Nippon Shinyaku. MT reports honoraria from Janssen. SM, YS, and MS are employees of Meiji Seika Pharma Co., Ltd., Tokyo, Japan. TT reports consulting fees from Kyowa Kirin, Nippon Shinyaku, Takeda, Roche Diagnostics and Meiji Seika Pharma; and honoraria from AbbVie, Astellas, AstraZeneca, Asahi Kasei Pharma, Kyowa Kirin, Novartis, Chugai, Gilead, Pfizer, Janssen, Otsuka, Bristol-Myers Squibb, Takeda, Daiichi Sankyo, Nippon Shinyaku, MSD, Meiji Seika Pharma, Nippon Kayaku, SymBio, Genmab, Sanofi, Amgen, Kissei, Sysmex, Pharma Essentia Japan, Ono and Roche Diagnostics; research funding from Otsuka, Asahi Kasei Pharma, Gilead, Priothera SAS, LUCA Science, Pharma Essentia Japan, Kyowa Kirin, Sumitomo Pharma, Chugai, JCR Pharma, Nippon Kayaku and Fuji Pharma. KH reports consulting fees from Meiji Seika Pharma; and honoraria from Daiichi-Sankyo, Genmab, and Yakult. YM reports honoraria from Kyowa Kirin, and Novartis; research funding from Chugai, and Nippon Shinyaku; and scholarships from Chugai, Eisai, and Otsuka. The remaining authors declare no competing financial interests.
: The Institutional Review Board of each investigational site approved the trial protocol, and the study conduct conformed with all legal and regulatory requirements including Good Clinical Practice ordinance and the Declaration of Helsinki of 1975, as revised in 2013. All patients (and/or their legal guardians, if aged ≥12 and <18 years) provided written informed consent for participation.
